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ABSTRACT
Introduction: Affordable treatment alternatives
are needed to prevent and treat chronic
obstructive pulmonary disease (COPD) exacer-
bations and reduce the economic burden of
COPD. This study evaluated whether the effec-
tiveness of Steri-NebTM (Teva Pharmaceuticals,
Inc.), the comparator ipratropium/salbutamol
(I/S) nebulizer solution, is non-inferior to Duo-
Neb (Mylan Specialty L.P.), the originator with
the same chemical composition, the first
FDA-approved product of this kind, for the
prevention of COPD exacerbations. I/S com-
parator versus originator safety also was exam-
ined. Both the I/S comparator and the
originator are indicated (EU/USA) for bron-
chospasm management in patients with COPD.
Methods: This matched, historical USA cohort
study used ClinformaticsTM claims data and
included a 1-year baseline, starting 1 year before
the index prescription date, and 1-year outcome
period. Patients received either I/S comparator
or originator treatment. The primary outcome
was rate of moderate and severe COPD exacer-
bations. Non-inferiority for I/S comparator ver-
sus originator was satisfied if the 95%
confidence interval (CI) upper limit for mean
difference in proportions between treatments
was \15%. The secondary outcome examined
safety through rate of adverse events (AEs).
Results: After matching, 550 I/S comparator
and 1535 originator patients were included.
Adjusted upper 95% CI for the difference in
proportion of patients experiencing moderate
and severe exacerbations between I/S compara-
tor and originator cohorts was 0.092 (9.2%),
and for severe exacerbations was 0.040 (4.0%),
demonstrating non-inferiority. No significant
differences were found in rates of moderate and
severe exacerbations (rate ratio [RR] 0.96; 95%
CI 0.89, 1.04), severe exacerbations (RR 1.00;
95% CI 0.81, 1.24), or any AE (RR 1.06; 95% CI
0.92, 1.22) after adjusting for baseline
confounders.
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Conclusion: The real-world clinical outcomes
of this matched cohort study support the I/S
comparator as non-inferior to the originator,
providing an effective and safe treatment alter-
native for COPD exacerbations.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD)
is a common, progressive, inflammatory disease
characterized by persistent airflow limitation [1].
COPD is predicted to be the 3rd leading cause of
death worldwide by the year 2030 [2], the 7th
leading cause of disability-adjusted life years lost
worldwide by 2030 [3], and is currently a prin-
cipal cause of morbidity and mortality world-
wide [1]. Exacerbations, the acute worsening of
respiratory symptoms that may require a change
in medication, often occur in patients with
COPD. Exacerbations are known to accelerate
lung function decline and are associated with
significantmortality [1, 4].Of the total economic
burden of COPD on the health care system, the
greatest proportion is due to COPD exacerba-
tions [1]. Notably, hospitalizations are the pri-
mary component of COPD-related medical costs
and prevention of exacerbations can reduce this
economic burden [5–7].
The Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines recommend
the use of short-acting b2-agonists (SABAs) with
or without short-acting muscarinic antagonists
(SAMAs) as the preferred bronchodilators for
the treatment of exacerbations [1, 4]. In line
with effective treatment of an exacerbation
serving to minimize its impact and prevent
hospitalizations and subsequent exacerbation
relapse [4, 8], the American College of Chest
Physicians and Canadian Thoracic Society
Guidelines advises combination treatment with
SAMA/SABA to prevent moderate COPD exac-
erbations [9]. A nebulized combination inhala-
tion solution of ipratropium bromide (a SAMA)
and salbutamol sulfate (a SABA) for the treat-
ment and prevention of COPD exacerbations
was first licensed in the USA as the originator
(DuoNeb, Mylan Specialty L.P., formerly Dey
Pharma, L.P.). Ipratropium/salbutamol com-
parator (I/S Steri-NebTM, Teva Pharmaceuticals,
Inc.) is a generic version of the originator with
the same chemical composition as the origina-
tor, and both are indicated for bronchospasm in
patients with COPD [10, 11]. The nebulized
solutions simultaneously deliver ipratropium
bromide and salbutamol sulfate, and effects are
produced on both muscarinic and b2-adrenergic
receptors in the lung [10]. The anticholinergic
effects of inhaled ipratropium bromide inhibit
vagally mediated reflexes by antagonizing the
muscarinic action of acetylcholine and result in
bronchodilation that is primarily local, selective
to the lung, and not systemic [12, 13]. Salbuta-
mol, a b2-adrenoceptor agonist, results in
relaxation of the airway smooth muscle from
the trachea to the terminal bronchioles and
protects against bronchoconstrictor challenges
[12, 13]. This combination has been shown to
produce enhanced bronchodilation compared
with that provided by each drug alone [14, 15].
Pharmacologicmanagement that can prevent
and treat COPD exacerbations reduces overall
costs; however, these medications can be
expensive, creating the need for affordable
treatment alternatives. The present analysis
examined real-life clinical management of a
broad population of USA COPD patients using a
historic cohort study of patients enrolled in a
healthcare claims database. The aim of the cur-
rent study was to evaluate whether the I/S com-
parator is non-inferior in effectiveness to the
originator in patients with COPD. I/S compara-
tor versus originator safety also was examined.
METHODS
Study Design and Population
The study protocol was registered with the
European Network of Centres for
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Pharmacoepidemiology and Pharmacovigilance
(ENCePP; ENCePP/SDPP/7753). The analyses
and the dissemination of the results were
approved by the advisory group and were con-
ducted in accordance with the Respiratory
Effectiveness Group (REG) standards [16] and
the ENCePP Code of Conduct. The study was a
matched, historical cohort study, using anony-
mous data from the ClinformaticsTM Data Mart
(CDM) database. The CDM is a patient longi-
tudinal database containing retrospective
claims data (2000–2012) from an employed,
commercially insured USA population. The
database contains primary and secondary care
medical claims, pharmacy claims, laboratory
results, and pricing information.
The study period comprised a 1-year baseline
period preceding and including the index pre-
scription date, followed by a 1-year outcome
period after the index prescription date. The
index prescription date was defined as the date
at which COPD patients who were not on
SAMA/SABA nebulisers in baseline received
their first prescription for I/S comparator or
originator. The analysis included CDM data
entered from January 2007 until the last avail-
able data included in the CDM (September
2012). The January 2007 study onset was
determined by the FDA approval date of the I/S
comparator in the USA (January 2008 versus the
originator March 2001) to ensure the patient
cohorts received treatment within a similar
timeframe. The outcome period was used to
compare drug effectiveness and safety between
cohorts.
Study Drugs
The comparator drug was I/S solution for
inhalation via nebulizer, containing iprat-
ropium bromide (0.5 mg) and salbutamol sul-
fate (3.0 mg) in a sterile single-dose, 3-mL
ampule. Inactive ingredients include sodium
chloride and 1 N hydrochloric acid for pH
adjustment. The originator drug contained
ipratropium bromide (0.5 mg) and salbutamol
sulfate (3.0 mg) solution for inhalation via
nebulizer. Patients received the originator as a
single-dose, 3-mL sterile solution for
nebulization in low-density polyethylene uni-
t-dose vials. Inactive ingredients include
sodium chloride, hydrochloric acid for pH
adjustment, and edetate disodium USP (a
chelating agent). The prescribing information
for both the I/S comparator and originator
indicates administration of the inhalation
solution via jet nebulizer connected to an air
compressor with an adequate air flow using a
face mask or mouthpiece [10, 11]. Specifically
noted in the prescribing information for both
products is the Pari-LC-PlusTM nebulizer con-
nected to a PRONEBTM compressor system.
Inclusion and Exclusion Criteria
Patients aged C35 years with 2 years of contin-
uous practice data and medical insurance cov-
erage, including 12 months prior to and
12 months following the index prescription
date for either I/S comparator or originator, and
C1 prescription for either I/S comparator or
originator within the outcome period were
included in the study. Patients who had C1
prescription for a SAMA/SABA nebulizer during
baseline were excluded.
Prior and Maintenance Therapies
Baseline respiratory drugs included SABA inha-
lers/nebulizers, SAMA inhalers/nebulizers,
long-acting b2-agonists (LABAs), long-acting
muscarinic antagonists (LAMAs), and inhaled
corticosteroids (ICS). Additional information
about baseline respiratory drugs is provided in
Table 2.
Study Outcomes
The primary outcome was the rate of moderate
and severe exacerbations and rate of severe
exacerbations during the outcome period. A
moderate-to-severe exacerbation was defined as
an event in which the patient had any of the
following: COPD-related emergency depart-
ment (ED) visit, COPD-related inpatient
admission, acute course of oral corticosteroids
for lower respiratory event(s), or antibiotic
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prescription for lower respiratory event(s). Any
hospitalizations, oral corticosteroids, or antibi-
otic prescriptions occurring within 2 weeks of
each other were considered to be the result of
the same exacerbation and were counted only
once. A severe COPD exacerbation was defined
as any event that resulted in COPD-related ED
visits or inpatient hospital admissions.
The secondary outcome included the rate of
any adverse events (AEs) and the rate of AEs by
system organ class (SOC) between the I/S com-
parator versus originator cohorts during the
outcome period. Potential AEs to search within
the CDM database were identified using the I/S
comparator and originator Summary of Product
Characteristics (SPC)/Prescribing Information
list of possible AEs [10, 11]. The SPC-listed AEs
identified in the database are proxies for possi-
ble AEs rather than actual known AEs in
response to treatment. Their occurrence indi-
cates the patient had a consultation associated
with the AE. The list of potential AEs derived
from the SPC was identified in the CDM data-
base using International Classification of Dis-
eases, Ninth Revision (ICD-9-CM) codes. For
comparison between the I/S comparator and
originator cohorts, the AEs were classified by
MedDRA (available at http://www.meddra.org/)
SOC.
Statistical Analyses
Exploratory analysis of baseline variables for the
I/S comparator and originator cohorts was
conducted for data validation and to establish
whether the analysis would benefit from
matching. For variables measured on the inter-
val/ratio scale, a t test (normal distribution) or
Mann–Whitney U test (skewed data) was used;
for categorical variables, a Chi squared test was
used. Statistical significance was set at P\0.05.
Patients were characterized according to age,
gender, year of receipt of index prescription for
I/S comparator or originator, evidence of
comorbidities (including comorbidity score
calculated via the Charlson Comorbidity Index
[CCI] [17]), baseline use of prescriptions for
non-steroidal anti-inflammatory drugs and beta
blockers, prior respiratory maintenance
therapies, acute oral corticosteroids, antibiotic
prescriptions for lower respiratory events, base-
line COPD exacerbations, and occurrence of
AEs.
Based on differences identified through
exploratory analysis of baseline variables, indi-
vidual patients from each cohort were matched
to ensure comparison of similar patients. Exact
matching for categorical variables and coars-
ened exact matching for numeric variables were
used to match patients using 1:1, 2:1, and 3:1
(originator: I/S comparator) nearest-neighbor
matching, without replacement. Mixed match-
ing (1:1, 2:1, 3:1) was used to maintain overall
statistical power due to low patient numbers
after applying inclusion/exclusion criteria.
Matching variables, such as demographic data,
disease comorbidity, and indicators of disease
severity, were considered for selection using a
combination of baseline data analysis and pre-
dictive modeling of baseline data in relation to
the primary outcome variable (independently
of treatment group). Final matching criteria
were age at receipt of index prescription for I/S
comparator or originator, subcohort, gender,
baseline number of moderate and severe exac-
erbations, baseline SABA prescribed daily dose,
and baseline ICS, LAMA, and LABA use.
In the power analysis, 40.8% of COPD
patients on SABA inhalers were expected to
have an exacerbation within a 1-year period
following treatment initiation [18]. Assuming a
40.8% proportion in the standard group and an
expected difference between the proportions of
0.000, the sample sizes required for adequate
statistical power in a two-group, large-sample
normal approximation, with a one-sided 0.05
significance level, are 536 and 1606 patients for
the I/S comparator and originator cohorts,
respectively. Previous randomized clinical
studies evaluating efficacy and safety in COPD
patients have reported that a 20% difference
between treatment groups is clinically signifi-
cant [19, 20]; therefore, a more stringent 15%
limit was used in the current study. Taken
together, this enabled an 80% power to show
that there was no statistical difference between
groups when the 95% CI upper limit of mean
difference in proportions between treatments
was\15%.
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For the primary outcome, non-inferiority for
I/S comparator versus originator was established
if the 95% CI upper limit of mean difference in
proportions between treatments of the rate of
moderate and severe exacerbations was\15%.
Conditional Poisson regression models used
empirical standard errors for more conservative
CI estimations and adjusted for potential base-
line confounders. Rates of exacerbations and
rates of AEs were compared between cohorts
using conditional logistic regression models
adjusted for potential baseline confounders and
presented as rate ratios (RR) with 95% CI.
Whereas the main analyses included all mat-
ched patients, a subgroup analysis also was
conducted using only the 3:1 matched patient
cohorts to ensure that I/S comparator patients
were not overrepresented in the main analysis.
The 3:1 matched subgroup analysis was pow-
ered at 73%. All study analyses were intent-to-
treat based on the C1 prescription for either I/S
comparator or originator that determined the
patient cohort assignment. Statistical analyses
were performed using SAS version 9.3 (SAS
Institute, Marlow, Buckinghamshire, UK).
RESULTS
A total of 6192 valid patient records were iden-
tified, including 5638 patients in the originator
cohort and 554 patients in the I/S comparator
cohort (Fig. 1). Following patient matching, a
total of 1535 and 550 patients were selected for
the originator and I/S comparator cohorts,
respectively (Fig. 2). The 3:1 matched subgroup
included a total of 1326 patients in the originator
cohort and 442 patients in the I/S comparator
cohort. Baseline characteristics, use of respira-
tory therapies, and AEs are summarized in
Tables 1, 2, and 3 (baseline comparisons in
unmatched patients are shown in Tables S1–S3).
The mean age of patients when they received
their first prescription for I/S comparator or
originator was 59 for the I/S comparator cohort
and 58 for the originator cohort. Approximately
39% of patients in both cohorts were male.
Following matching, some differences in
baseline characteristics remained between
cohorts, including year of index prescription,
age at index prescription, comorbidities,
comedications, use of respiratory-related drugs,
and AE prevalence (Tables 1, 2, 3). The per-
centage of patients was greater in the I/S com-
parator versus originator cohort across these
clinical characteristics, indicating poorer health
and more prevalent AEs in the I/S comparator
cohort at baseline.
COPD Exacerbations
The I/S comparator was non-inferior to the
originator for the primary outcome of rate of
moderate and severe COPD exacerbations and
Fig. 1 Flow diagram of patient population. I/S ipratropium/salbutamol, SABA short-acting b2-agonist, SAMA short-acting
muscarinic antagonist
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rate of severe COPD exacerbations, with an
adjusted upper 95% CI for the difference in
proportions for the I/S comparator versus the
originator of 0.092 (9.2%) and 0.040 (4.0%),
respectively, which were below the non-inferi-
ority criterion of \15%. In the 3:1 matched
subgroup analysis, the adjusted upper 95% CI
for the difference in proportions for I/S com-
parator versus originator for moderate and sev-
ere exacerbations was 0.082 (8.2%) and for
severe exacerbations was 0.028 (2.8%).
Additionally, there was no significant differ-
ence in the rate of moderate and severe exac-
erbations (adjusted RR 0.96; 95% CI 0.89, 1.04)
or severe exacerbations (adjusted RR: 1.00; 95%
CI: 0.81, 1.24) between the I/S comparator and
originator cohorts (Table 4; Fig. 3). The 3:1
matched subgroup analysis was consistent with
the main analysis and showed no significant
difference between cohorts (Table 4).
Safety
The rate of any AEs did not significantly differ
between the I/S comparator and originator
cohorts during the 1-year outcome period (ad-
justed RR 1.06; 95% CI 0.92, 1.22; Table 4;
Fig. 4). For the majority of AEs by system organ
class (SOC), no significant differences were
observed between cohorts (Table 5). Significant
differences were found between I/S comparator
and originator cohorts for metabolic and
nutritional disorders (8% versus 5.5%, respec-
tively), psychiatric disorders (26.9% versus
20.5%), and nervous system disorders (9.5%
versus 6.2%).
DISCUSSION
Within this historical, matched study popula-
tion of patients with COPD, the I/S comparator
was non-inferior to the originator in effective-
ness for the prevention of moderate and severe
exacerbations of COPD. The upper limit of the
95% CI for the difference in proportions of the
I/S comparator versus originator cohorts was
\12%, thus meeting the non-inferiority
threshold of\15%. The 3:1 subgroup analyses
were consistent with the outcomes of the main
analyses.
Fig. 2 Flow diagram of study inclusion criteria for matched patients. ICS inhaled corticosteroid, I/S ipratropium/
salbutamol, LABA long-acting b2-agonist, LAMA long-acting muscarinic antagonist.
aSoftware was used to randomly select
unique matched patients
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Table 1 Baseline demographics and clinical characteristics of matched patients
I/S comparator n5 550 Originator n5 1535 P valuea
Year index prescription was received, mean ± SD 2011 ± 0.8 2006 ± 0.7 \0.001
Age when index prescription was received, mean ± SD 58.8 ± 12.0 58.3 ± 11.3 0.020
Age, categories, n (%) \0.001
35–60 years 321 (58.4) 933 (60.8)
60–80 years 191 (34.7) 601 (39.2)
[80 years 38 (6.9) 1 (0.1)
Gender, n (%) Males 214 (38.9) 591 (38.5) N/A
Asthma diagnosis, n (%) 258 (46.9) 757 (49.3) 0.239
Rhinitis diagnosis, n (%) 134 (24.4) 345 (22.5) 0.435
GERDb, n (%) 214 (38.9) 506 (33.0) 0.011
Ischemic heart disease diagnosis, n (%) 154 (28.0) 360 (23.5) 0.030
Prescribed NSAIDs, n (%) 201 (36.5) 533 (34.7) 0.456
Prescribed beta blockers, n (%) 164 (29.8) 377 (24.6) 0.019
Charlson Comorbidity Index scorec, n (%) \0.001
0 70 (12.8) 256 (16.7)
1–4 225 (41.1) 689 (44.9)
C5 253 (46.2) 588 (38.4)
Moderate and severe COPD exacerbations in the year before and including the date the index prescription was
received, n (%)
NA
0 164 (29.8) 470 (30.6)
1 148 (26.9) 418 (27.2)
2 100 (18.2) 273 (17.8)
C3 138 (25.1) 374 (24.4)
Severe COPD exacerbations in the year before and including the date the index prescription was received, n (%) 0.488
0 363 (66.0) 1049 (68.3)
1 127 (23.1) 332 (21.6)
2 39 (7.1) 81 (5.3)
C3 21 (3.8) 73 (4.8)
Patients were matched on the basis of gender, moderate and severe COPD exacerbations in baseline (categorized), ICS use
in baseline (yes/no), LABA use in baseline (yes/no), LAMA use in baseline (yes/no), and age (± 6 years). Data for
unmatched cohorts are provided in Table S1
Items italicized were among the ﬁnal matching criteria
COPD chronic obstructive pulmonary disease, GERD gastroesophageal reﬂux disease, I/S ipratropium/salbutamol, NSAIDs
nonsteroidal anti-inﬂammatory drugs, SD standard deviation
a P value based on conditional logistic regression
b Includes diagnosis and/or therapy
c Charlson Comorbidity Index [17] is a method of predicting 1-year mortality for a patient who may have a range of
comorbid conditions that are each assigned a ‘‘weight’’ corresponding to risk of death associated with the condition; scores
are then summed to give a total score predicting mortality
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Table 2 Baseline use of respiratory therapies in matched patients
I/S comparator n5 550 Originator n5 1535 P valuea
C1 Prescription for respiratory therapies in the year before patients received the index prescription, n (%)
ICS 251 (45.6) 686 (44.7) N/A
LABA 215 (39.1) 588 (38.3) N/A
LAMA 70 (12.7) 174 (11.3) N/A
SAMA nebulizer 36 (6.5) 82 (5.3) 0.365
SAMA inhaler 7 (1.3) 24 (1.6) 0.634
SABA nebulizer 81 (14.7) 213 (13.9) 0.742
SABA inhaler 244 (44.4) 600 (39.1) 0.018
Prescribed daily dose of SABA inhalers (lg)b in the year before patients received the index prescription,
categorized, n (%)
0.674
0 306 (55.6) 935 (60.9)
1–200 140 (25.5) 258 (16.8)
[200 104 (18.9) 342 (22.3)
Prescriptions of acute oral corticosteroidsc for lower respiratory eventsd in the year before patients received the
index prescription, n (%)
0.362
0 261 (47.5) 745 (48.5)
1 130 (23.6) 380 (24.8)
2 60 (10.9) 168 (10.9)
C3 99 (18.0) 242 (15.8)
Prescriptions for antibiotics for lower respiratory eventsd in the year before patients received the index
prescription, n (%)
\0.001
0 233 (42.4) 685 (44.6)
1 141 (25.6) 399 (26.0)
2–3 117 (21.3) 345 (22.5)
C4 59 (10.7) 106 (6.9)
Patients were matched on the basis of gender, moderate and severe COPD exacerbations in baseline (categorized), ICS use
in baseline (yes/no), LABA use in baseline (yes/no), LAMA use in baseline (yes/no), and age (±6 years). Data for
unmatched cohorts are provided in Table S2
Items italicized were among the ﬁnal matching criteria
ICS inhaled corticosteroid, I/S ipratropium/salbutamol, LABA long-acting b2-agonist, LAMA long-acting muscarinic
antagonist, SABA short-acting b2-agonist, SAMA short-acting muscarinic antagonist
a P value based on conditional logistic regression
b Daily dose was calculated as [(count of inhalers 9 doses in pack)/365] 9 lg strength
c Deﬁned as all courses where dosing instructions suggest exacerbation treatment and/or unlikely to be maintenance
treatment
d Deﬁned as a COPD-related emergency department visit/hospital admission/ambulatory visit or a respiratory investigation
recorded within a ± 5-day window from the prescription
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Table 3 Baseline prevalence of adverse events in matched patients
I/S comparator n5 550 Originator n5 1535 P valuea
Any AE, n (%) \0.001
0 115 (20.9) 510 (33.2)
1 72 (13.1) 241 (15.7)
C2 363 (66.0) 784 (51.1)
Immune system disorders, n (%) 0.264
0 546 (99.3) 1530 (99.7)
1 2 (0.4) 4 (0.3)
C2 2 (0.4) 1 (0.1)
Metabolism and nutrition disorders, n (%) 0.005
0 517 (94.0) 1480 (96.4)
1 14 (2.5) 33 (2.1)
C2 19 (3.5) 22 (1.4)
Psychiatric disorders, n (%) \0.001
0 432 (78.5) 1316 (85.7)
1 42 (7.6) 66 (4.3)
C2 76 (13.8) 153 (10.0)
Nervous system disorders, n (%) 0.676
0 510 (92.7) 1439 (93.7)
1 28 (5.1) 59 (3.8)
C2 12 (2.2) 37 (2.4)
Eye disorders, n (%) 0.038
0 511 (92.9) 1463 (95.3)
1 19 (3.5) 38 (2.5)
C2 20 (3.6) 34 (2.2)
Skin and subcutaneous tissue disorders, n (%) 0.852
0 543 (98.7) 1514 (98.6)
1 5 (0.9) 15 (1.0)
C2 2 (0.4) 6 (0.4)
Cardiovascular disorders, n (%) 0.043
0 380 (69.1) 1128 (73.5)
1 41 (7.5) 102 (6.6)
C2 129 (23.5) 305 (19.9)
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Differences between the cohorts at baseline
showed that the I/S comparator cohort was
older, experienced greater comorbid illness (as
assessed by the CCI score) [17], and used SABA
inhaler respiratory therapy and antibiotics for
lower respiratory events more frequently. Base-
line differences in AEs were also noted, with the
I/S comparator cohort reporting a greater fre-
quency of AEs for the outcome of any AE and
for the AEs by SOC of metabolic and nutritional
disorders, psychiatric disorders, eye disorders,
cardiovascular disorders, respiratory, thoracic,
and mediastinal disorders, musculoskeletal and
connective tissue disorders, and gastrointestinal
disorders during the baseline period. At the
1-year timepoint, greater frequency of meta-
bolic and nutritional disorders (i.e., hypokale-
mia, urinary retention), psychiatric disorders
(i.e., restlessness, memory disorders, anxiety),
and nervous system disorders (i.e., headache,
tremor, dizziness) was shown for patients in the
I/S comparator cohort compared with the orig-
inator cohort. Although the I/S comparator
cohort showed statistically significant
differences compared with the originator
cohort, this was likely due to the large sample
sizes as the percentage differences between
cohorts were small. Additionally, the differ-
ences in AEs at the 1-year timepoint were con-
sistent with the differences between cohorts at
baseline. Altogether, this suggests the differ-
ences between cohorts in AEs are unlikely rela-
ted to treatment.
The current analyses help to address a critical
need for improved understanding of real-life
clinical outcomes and treatment use in patients
with COPD. While randomized clinical trials
examining COPD treatment provide essential
outcome data with high internal validity, the
study population typically includes highly selec-
ted patients which limits generalizability to the
real-life clinical practice COPD population [21].
Alternatively, analyses of real-world clinical
practice databases that include the broad popu-
lation of patients receiving treatment, such as in
the current study, address the generalizability of
treatment outcomes in real-life clinical manage-
ment of diverse patients [22]. Strengths of the
Table 3 continued
I/S comparator n5 550 Originator n5 1535 P valuea
Respiratory, thoracic and mediastinal disorders, n (%) \0.001
0 282 (51.3) 964 (62.8)
1 120 (21.8) 286 (18.6)
C2 148 (26.9) 285 (18.6)
Musculoskeletal and connective tissue disorders, n (%) 0.025
0 495 (90.0) 1423 (92.7)
1 25 (4.5) 57 (3.7)
C2 30 (5.5) 55 (3.6)
Gastrointestinal disorders, n (%) \0.001
0 413 (75.1) 1255 (81.8)
1 49 (8.9) 99 (6.4)
2 88 (16.0) 181 (11.8)
Patients were matched on the basis of gender, moderate and severe COPD exacerbations in baseline (categorized), ICS use
in baseline (yes/no), LABA use in baseline (yes/no), LAMA use in baseline (yes/no), and age (±6 years). Data for
unmatched cohorts are provided in Table S3
AE adverse event, I/S ipratropium/salbutamol
a P value based on conditional logistic regression
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current study include the largepatientpopulation
available within the database of commercially
insured USA patients that allowed the matching
of patients on potential baseline confounders.
The statistical analysis plan, study population,
and outcomes were conceived prior to any anal-
yses to ensure all potentially relevant variables for
characterizing patients were included, and that
the key outcomes could be assessed. The 1-year
baseline and outcome periods allowed recording
of measurable changes in outcomes and seasonal
changes in respiratory disease and its related
conditions. The study was conducted in accor-
dancewiththeENCePPCodeofConduct andREG
standards [16]. Nevertheless, given the inherent
limitations of database studies, such as potential
confounding factorswith internal validity, results
from this study should ideally be considered in
conjunctionwith those of randomized controlled
trials. Ideally, a direct comparison of our obser-
vational database study findings with a random-
ized controlled trial examining a highly similar
COPD patient population with a similar rate of
exacerbationswould be conducted to confirm the
reliability and validity of our observational data-
base outcomes [23]; however, for the I/S com-
parator versus originator, such a randomized
controlled trial is not yet available. Thus, the
current study findings should be interpreted with
appropriate caution.
COPD exacerbations are clinically meaningful
events [4]with significanthealthcarecosts [24–26].
Considered the ‘‘stroke of the lungs,’’ COPD exac-
erbations initiate a catastrophic cascade of
increased symptoms, decline in lung function,
reduced exercise/physical function, increased
hospitalization risk, lower quality of life, and
accelerated disease progression [27]. Rapid health
decline has been demonstrated following a second
severe exacerbation, with progressively increased
risk of more frequent subsequent severe exacerba-
tions and increased mortality rate [28]. Patients
with severe COPD exacerbation that required
hospitalization showed physical and functional
impairment during hospitalization with contin-
ued worsening in upper and lower limb muscle
strength and postural steadiness through 1 month
following hospital discharge, and significant
decline in physical function (as assessed by the
2-min step-in-place test) from discharge to
1-month follow-up [29]. In addition to physical
decline and increased mortality risk, the critical
need for effective prevention of acute exacerba-
tions is indicated by the persistence of decreased
quality of life and social and emotional impair-
ments that follow exacerbations, including
patients with moderate disease [30].
Given the high prevalence and burden of
COPD, the prevention and effective treatment of
COPD exacerbations are key clinical goals [1]. To
minimize the impact of a current exacerbation
and prevent the development of subsequent
exacerbations, short-acting inhaled b2-agonists
with or without short-acting anticholinergics are
usually the preferred bronchodilators [4]. In the
outpatient setting, SABA and SAMA bron-
chodilators are essential in the treatment of
COPD exacerbations, with the goal to disrupt
decompensation in lung function, prevent hos-
pitalization, and prevent relapse [8]. The GOLD
guidelines recommend a combination of bron-
chodilators of different pharmacological classes
as it may improve efficacy and decrease AE risk
versus increasing the dose of single agents [1].
Similarly, in patients with moderate-to-severe
COPD, the American College of Chest Physicians
and Canadian Thoracic Society Guidelines sug-
gests combination treatment with SAMA/SABA
to prevent moderate COPD exacerbations [9].
The clinical benefit of a combined SAMA/SABA
bronchodilator with the components iprat-
ropium-salbutamol compared with each individ-
ual component on outcomes such as forced
expiratory volume in 1 s (FEV1) has previously
been demonstrated [15, 31]. Additionally, using a
healthcare claims database for a retrospective
pharmacoeconomic analysis of COPD exacerba-
tions and patient healthcare use, it was found that
a combined ipratropium-salbutamol bron-
chodilator significantly decreased morbidity and
financialburdenasassessedthroughEDorhospital
use compared with treatment using the separate
components [32]. One hypothesized mechanism
for improved outcomes with combined SAMA/
SABA treatment is decreased daily variability in
patient bronchodilator response; i.e., reduced
response to one bronchodilator on a given treat-
ment day is moderated by the second bron-
chodilator with a differing mechanism of action
[33]. Consistent with this hypothesized
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Table 4 Percentage of patients with COPD exacerbation and any AE by number of events during the outcome period in
matched patients
All matched patients 3:1 Matched patient subgroup
I/S comparator Originator P valuea I/S comparator Originator P valuea
n 5 550 n5 1535 n 5 442 n5 1326
Primary outcome
COPD moderate and severe exacerbations, n (%) 0.382 0.312
0 88 (16.0) 311 (20.3) 72 (16.3) 272 (20.5)
1 155 (28.2) 386 (25.1) 125 (28.3) 344 (25.9)
2 114 (20.7) 299 (19.5) 94 (21.3) 252 (19.0)
C3 193 (35.1) 539 (35.1) 151 (34.2) 458 (34.5)
RR (95% CI) 0.96 (0.89,
1.04)b
1.00 0.95 (0.87,
1.04)c
1.00
COPD severe exacerbations, n (%) 0.929 0.669
0 394 (71.6) 1082 (70.5) 318 (71.9) 925 (69.8)
1 93 (16.9) 274 (17.9) 75 (17.0) 241 (18.2)
2 31 (5.6) 108 (7.0) 22 (5.0) 96 (7.2)
C3 32 (5.8) 71 (4.6) 27 (6.1) 64 (4.8)
RR (95% CI) 1.00 (0.81,
1.24)d
1.00 0.94 (0.76,
1.19)e
1.00
Secondary outcome
Any AEf, n (%) 0.107 0.118
0 123 (22.4) 380 (24.8) 99 (22.4) 334 (25.2)
1 66 (12.0) 216 (14.1) 53 (12.0) 181 (13.7)
C2 361 (65.6) 939 (61.2) 290 (65.6) 811 (61.2)
RR (95% CI) 1.06 (0.92,
1.22)g
1.00 1.07 (0.92,
1.24)g
1.00
Patients were matched on the basis of gender, moderate and severe COPD exacerbations in baseline (categorized), ICS use
in baseline (yes/no), LABA use in baseline (yes/no), LAMA use in baseline (yes/no), and age (±6 years)
AE adverse event, CI conﬁdence interval, COPD chronic obstructive pulmonary disease, I/S ipratropium/salbutamol, RR
rate ratio
a P value represents conditional logistic regression results
b Adjusted for baseline COPD exacerbations (categorized) and consultations
c Adjusted for baseline COPD exacerbations (categorized)
d Adjusted for baseline asthma diagnosis, baseline GERD and/or drugs, and baseline hospitalizations (categorized)
e Adjusted for baseline asthma diagnosis, beta blocker prescriptions, baseline GERD and/or drugs, and baseline hospital-
izations (categorized)
f Any AE included the AEs reported in the I/S Comparator Summary of Product Characteristics
g Adjusted for year when patients received index prescription and baseline total AEs (categorized)
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mechanism, combined ipratropium-salbutamol
produced lower daily variability in FEV1 compared
with monotherapy with either agent, resulting in
increasedstabilityofairwaytonethatmayimprove
symptom control [33]. The current analysis show-
ing non-inferiority in effectiveness for the I/S
comparator versus the originator supports the
availability of another treatment alternative for
combination SAMA/SABA treatment in patients
with COPD who experience exacerbations.
A limitation associated with the use of a
database is the possibility of coding errors or
inconsistencies, although these are not expec-
ted to differentially affect the studied cohorts.
The inclusion criteria of respiratory medication
and age 35 or older was used to identify patients
with COPD as the database does not specifically
contain ‘‘COPD diagnosis’’ as a variable. As
SAMA/SABA medication is more commonly
prescribed for patients with COPD than asthma,
it is likely that most, if not all, patients had
Fig. 3 Percentage distribution of patients by number of moderate to severe exacerbations in the outcome period. CI
conﬁdence interval, I/S ipratropium/salbutamol, RR rate ratio. Adjusted for baseline COPD exacerbations (categorized) and
consultations
Fig. 4 Percentage distribution of patients by number of any adverse events (AEs) in the outcome period. CI conﬁdence
interval, I/S ipratropium/salbutamol, RR rate ratio. Adjusted for year when patients received the index prescription and
baseline total AEs (categorized)
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Table 5 AE categories during the outcome period in matched patients
I/S comparator n 5 550 Originator n5 1535 P valuea
Immune system disorders (hypersensitivity reactions with angioedema, anaphylactic reactions), n (%) 0.525
0 546 (99.3) 1526 (99.4)
1 2 (0.4) 7 (0.5)
C2 2 (0.4) 2 (0.1)
RR (95% CI)b 1.52 (0.43, 5.28) 1.00
Metabolic and nutritional disorders (hypokalemia, urinary retention), n (%) 0.011
0 506 (92.0) 1451 (94.5)
1 22 (4.0) 52 (3.4)
C2 22 (4.0) 32 (2.1)
RR (95% CI)c 1.01 (0.40, 2.54) 1.00
Psychiatric disorders (restlessness, memory disorders, anxiety), n (%) 0.004
0 402 (73.1) 1221 (79.5)
1 43 (7.8) 89 (5.8)
C2 105 (19.1) 225 (14.7)
RR (95% CI)c,d 1.15 (0.61, 2.15) 1.00
Nervous system disorders (headache, tremor, dizziness), n (%) 0.032
0 498 (90.5) 1439 (93.7)
1 35 (6.4) 59 (3.8)
C2 17 (3.1) 37 (2.4)
RR (95% CI)c,e 1.48 (0.97, 2.26) 1.00
Eye disorders (cataract, glaucoma, accommodation disorders, mydriasis), n (%) 0.457
0 510 (92.7) 1415 (92.2)
1 22 (4.0) 58 (3.8)
C2 18 (3.3) 62 (4.0)
RR (95% CI)c,f 0.72 (0.47, 1.12) 1.00
Skin and subcutaneous tissue disorders (rash, urticaria, pruritus, hyperhidrosis), n (%) 0.983
0 538 (97.8) 1503 (97.9)
1 9 (1.6) 22 (1.4)
C2 3 (0.5) 10 (0.7)
RR (95% CI)b 0.82 (0.36, 1.87) 1.00
Cardiovascular disorders (palpitations, tachycardia, cardiac arrhythmias, atrial ﬁbrillation, myocardial ischemia,
peripheral vasodilation, coronary ischemic disease), n (%)
0.817
0 371 (67.5) 1032 (67.2)
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COPD. Additionally, due to the complexities of
the database, the SPC-listed AEs used to indicate
AEs during treatment are proxies for potential
AEs rather than known actual AEs in response to
treatment. Although their occurrence indicates
that the patient had a consultation associated
with the AE, it is not known whether another
pre-existing condition was the cause of the AE.
As a result, the rate of AEs is likely to be
over-reported. The frequency of use of the I/S
comparator and originator, the nebulizer deliv-
ery system(s) used by patients, and mortality
rates could not be examined as these data were
not available in the database. The determina-
tion of the patient cohorts from C1 prescription
for either I/S comparator or originator and an
Table 5 continued
I/S comparator n 5 550 Originator n5 1535 P valuea
1 35 (6.4) 123 (8.0)
C2 144 (26.2) 380 (24.8)
RR (95% CI)c 1.25 (0.55, 2.83) 1.00
Respiratory, thoracic, and mediastinal disorders (laryngospasm, pharyngeal edema, throat irritation, hoarseness/
dysphonia, sinusitis, dyspnea, bronchospasm/paradoxical bronchospasm), n (%)
0.927
0 339 (61.6) 941 (61.3)
1 97 (17.6) 275 (17.9)
C2 114 (20.7) 319 (20.8)
RR (95% CI)c 0.66 (0.61, 1.01) 1.00
Musculoskeletal and connective tissue disorders (muscle cramps, myalgia), n (%) 0.625
0 495 (90.0) 1399 (91.1)
1 30 (5.5) 66 (4.3)
C2 25 (4.5) 70 (4.6)
RR (95% CI)c 0.74 (0.45, 1.20) 1.00
Gastrointestinal disorders (dry mouth, nausea, motility disorders [diarrhea, constipation, vomiting], mouth
edema, stomatitis), n (%)
0.274
0 415 (75.5) 1204 (78.4)
1 48 (8.7) 100 (6.5)
C2 87 (15.8) 231 (15.0)
RR (95% CI)c 1.03 (0.73, 1.44) 1.00
CI conﬁdence interval, I/S ipratropium/salbutamol, RR rate ratio
Patients were matched on the basis of gender, moderate and severe COPD exacerbations in baseline (categorized), ICS use
in baseline (yes/no), LABA use in baseline (yes/no), LAMA use in baseline (yes/no), and age (±6 years). Data for
unmatched cohorts are provided in Table S3
a P value represents conditional logistic regression
b No adjustments were made due to low numbers of AEs
c Adjusted for baseline level of corresponding AE
d Adjusted for age, year when patients received index prescription
e Adjusted for cardiac diagnosis and beta blockers
f Adjusted for age
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intent-to-treat analysis approach, though
appropriate for our safety analysis and real-life
varied respiratory cohort, may have attenuated
differences between cohorts in the examined
outcomes. Although the patient cohorts were
matched for baseline respiratory medication
use, the current study outcomes related to I/S
comparator and originator treatment should be
interpreted within the context of treatment
with multiple respiratory medications. Addi-
tionally, it is possible that the I/S comparator
and originator were used to treat rather than
prevent COPD exacerbations and this possibil-
ity could not be examined within the database.
Finally, the current study evaluated the treat-
ment effect in patient cohorts with first initia-
tion of the I/S comparator or originator. The
treatment effect of the I/S comparator among
patients who switched from prior use of the
originator could not be examined due to the
small sample size (n = 40) of this patient group;
this may be of interest for a future study.
CONCLUSIONS
In this matched cohort study of patients with
COPD, the I/S comparator demonstrated
non-inferiority versus the originator for the
prevention of moderate and severe exacerba-
tions. The real-world clinical outcomes of this
matched cohort study support the I/S com-
parator as a treatment alternative for the pre-
vention of COPD exacerbations. The availability
of the I/S comparator lower-cost generic treat-
ment alternative with equivalent effectiveness
may help reduce the cost of COPD exacerbation
prevention and provide potential economic
benefit in COPD care.
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